The USA Today story was actually a bit longer than the Associated Press story, so this was not a matter of word count limitations. In the end, it was a matter of which words were used and how the space was allocated. But the New York Times story was longest of the three – more than 1,000 words – and put that additional space to good use.
Once initial treatment for breast cancer is finished, there is a sense of loss of direction for many survivors. There are limited ways to reduce recurrence risk and mortality in the hope of a normal life span. This research adds to the evidence needed to make good decisions based on scientific study, and in particular adds data for decision-making by premenopausal patients.
Price is a significant issue with such a long-term medication and this story covered the issue well.
Our reviewers observed:
Our reviewers would have appreciated a more specific discussion of some of the age-specific issues in the study, such as those highlighted in a statement released by the Young Survival Coalition to members:
Overall, the patient population in this study tended to have low nodal involvement and most participants were over the age of 45 at time of initial diagnosis. 53% of the 10-year group were node negative and 54% of the five-year group were node negative. Only 16% of both groups had four or more nodes involved. Also, only 19% of the 10-year group and 18% of the five-year group were under age 45 at time of diagnosis. In both the five and 10-year group, 89% of study participants were postmenopausal at time of their entry into the ATLAS trial. In the five-year and 10-year groups , 47% and 48% of patients respectively had tumor sizes ranging from 1 to 20 mm (equivalent to 2 cm or under), while 39% and 38% respectively had tumor sizes between 21-50 mm (2 to 5 cm).
On this criterion, the AP story was not as strong as the competing USA Today story, which noted one woman’s experience with tamoxifen side effects (severe hot flashes, dry eyes, joint pain, weight gain, dryness “that made sex unbearably painful”).
AP only referred to “some troubling side effects” without specifying anything more than endometrial cancer.
The two women with breast cancer – both trained in the evaluation of evidence in the National Breast Cancer Coalition’s Project LEAD training – thought the brief reference to harms could have been more powerful with a reference to the statistics. “Patients need the facts,” one wrote. Another of their observations: the story could also have avoided weighting opinion by using the phrase “women balk at taking a preventative drug.” Making tough choices is one of the tasks of cancer patients.
Unlike the USA Today story, this story mentioned that the study had been published in the Lancet. There were two independent expert perspectives commenting on the evidence in this story – including a quote from an editorial writer in the same journal. Editorialists’ perspectives are low-hanging fruit which are often ignored in news stories – something we can never understand.
A strength of the article is its clear statement of sponsorship of the research, including AstraZeneca, which produces a brand of tamoxifen. USA Today didn’t mention this in its story. The article also indicated possible conflicts of interest among commentators.
The story adequately discusses and compares alternatives, including aromatase inhibitors Arimidex, Femara, Aromasin.
The article adequately discusses availability.
This story clearly presents the study’s importance regarding extended use of tamoxifen . The drug is not new, but the story clearly reports on its usefulness in particular patients.
With multiple sources, it’s clear the story did not rely on a news release.
Systematic, Criteria-Driven
Questions to ask about new Alzheimer’s drug research by @KatKStone incl:
-does study focus on patient outcomes or surrogate markers?
-does study rely on selective subgroups? (yield more favourable outcomes)
-who were the patients? https://www.healthnewsreview.org/2017/08/6-questions-to-ask-when-writing-and-reading-about-new-alzheimers-research/#.YRw5xNVXths.twitter @HealthNewsRevu
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like